The Current State of Targeted Agents in Rectal Cancer

Table 2

Pivotal randomized clinical trials of cetuximab in mCRC.

Study	Phase	Study design(regimen)	𝑁 +Cet/−	Results	Comment	Reference
1st line
CRYSTAL	III	FOLFIRI ± cetuximab	599/599	No difference in OS	PFS,OS benefit in KRAS-WT	[23]
OPUS	II	FOLFOX ± cetuximab	169/168	46 versus 36% RR	No difference in OS	[24]
CAIRO-2	III	CAPOX + beva ± cetuximab	377/378	9.4 versus 10.7 mo PFS		[25]
COIN	III	CAPOX or FOLFOX ± cetuximab	815/815	17 versus 17.9 mo OS	No difference in PFS,OS in KRAS-WT	[26]
NORDIC VII	III	FLOX ± cetuximab	194/185	19.7 versus 20.4 mo OS	No difference in PFS,OS in KRAS-WT	[27]
2nd line
BOND	II	Irinotecan ± cetuximab	218/111	22.9 versus 10.8% PR		[10]
CO.17	III	Cetuximab versus supportive care	287/285	6.1 versus 4.6 mo OS	9.5 versus 4.8 mo OS in KRAS-WT	[11, 28]

RR: Response rate, PFS: Progression-free survival, OS: Overall survival. KRAS-WT: KRAS wild type.